{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T23:38:25Z","timestamp":1787701105428,"version":"build-2784847793"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T00:00:00Z","timestamp":1763164800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council of Australia","doi-asserted-by":"publisher","award":["1066536"],"award-info":[{"award-number":["1066536"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council of Australia","doi-asserted-by":"publisher","award":["1142976"],"award-info":[{"award-number":["1142976"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Humoral immunity is thought to play a key role in the immunopathogenesis of chronic hepatitis B (CHB). Peaks in anti-HBs immune complexes (HBsAg-ICs) have been associated with subsequent HBsAg seroclearance. Discontinuation of nucleos(t)ide analog (NA) therapy can promote HBsAg seroclearance but also carries a risk of hepatitis flare. We evaluated the relationship between serum HBsAg-IC levels and hepatitis flare following NA cessation in HBeAg-negative CHB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In a multicentre prospective cohort of noncirrhotic HBeAg-negative CHB patients undergoing NA discontinuation, we conducted a nested case-control analysis (n = 38). Stored serum samples were tested for HBsAg-IC at end-of-treatment (EOT) and at serial timepoints off-treatment. Cases (n = 24) experienced a hepatitis flare (ALT &amp;gt;5\u00d7 upper limit of normal); controls (n = 14) did not. Associations between HBsAg-IC levels and clinical outcomes were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Serum HBsAg-ICs were detectable in 97% of participants at EOT. High HBsAg-IC levels (\u226540\u2005IU\/mL) at EOT were less frequent among those who developed hepatitis flare (8%) versus controls (57%, P = .002). Individuals treated with tenofovir (vs other NAs) had lower EOT HBsAg-IC levels. Longitudinal analysis revealed dynamic increases in HBsAg-IC levels during hepatitis flare, peaking with maximal ALT. Participants who experienced beneficial flares (\u22651 log\u2081\u2080 HBsAg reduction) had higher peak off-treatment HBsAg-IC levels compared to those with nonbeneficial flares.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Serum HBsAg-ICs are detectable in patients with CHB, and low levels at EOT are associated with the risk of hepatitis flare after NA cessation. These findings support the role of humoral immunity in CHB immunopathogenesis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trials Registration<\/jats:title>\n                    <jats:p>The study clinical trial ID is NCT02581033.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiaf569","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:15:33Z","timestamp":1762866933000},"page":"e621-e629","source":"Crossref","is-referenced-by-count":2,"title":["Anti-HBs Immune Complex Levels: A Novel Marker of Hepatitis Flare Following Nucleos(t)ide Analog Withdrawal in HBeAg-negative Chronic Hepatitis B"],"prefix":"10.1093","volume":"233","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0435-6138","authenticated-orcid":false,"given":"S J","family":"Hume","sequence":"first","affiliation":[{"name":"St Vincent's Hospital , Melbourne, Victoria ,","place":["Australia"]},{"name":"Department of Medicine, The University of Melbourne , Victoria ,","place":["Australia"]},{"name":"Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity , Melbourne, Victoria ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1176-5442","authenticated-orcid":false,"given":"K","family":"Visvanathan","sequence":"additional","affiliation":[{"name":"St Vincent's Hospital , Melbourne, Victoria ,","place":["Australia"]},{"name":"Department of Medicine, The University of Melbourne , Victoria ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Medicine, The University of Melbourne , Victoria ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Jackson","sequence":"additional","affiliation":[{"name":"Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity , Melbourne, Victoria ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1597-9421","authenticated-orcid":false,"given":"S","family":"Vogrin","sequence":"additional","affiliation":[{"name":"Department of Medicine, The University of Melbourne , Victoria ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7158-585X","authenticated-orcid":false,"given":"S A L","family":"Hall","sequence":"additional","affiliation":[{"name":"St Vincent's Hospital , Melbourne, Victoria ,","place":["Australia"]},{"name":"Department of Medicine, The University of Melbourne , Victoria ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G S","family":"Burns","sequence":"additional","affiliation":[{"name":"Western Health , Melbourne, Victoria ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P V","family":"Desmond","sequence":"additional","affiliation":[{"name":"St Vincent's Hospital , Melbourne, Victoria ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Ratnam","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Clinical Sciences at Monash Health, Monash University , Melbourne, Victoria ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M T","family":"Levy","sequence":"additional","affiliation":[{"name":"Liverpool Hospital , Sydney, New South Wales ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8131-2182","authenticated-orcid":false,"given":"R","family":"Sawhney","sequence":"additional","affiliation":[{"name":"Eastern Health , Melbourne, Victoria ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6374-1525","authenticated-orcid":false,"given":"S I","family":"Strasser","sequence":"additional","affiliation":[{"name":"Royal Prince Alfred Hospital , Sydney, New South Wales ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M C","family":"Ngu","sequence":"additional","affiliation":[{"name":"Concord Hospital , Sydney, New South Wales ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Sinclair","sequence":"additional","affiliation":[{"name":"Austin Health , Melbourne, Victoria ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Meredith","sequence":"additional","affiliation":[{"name":"Bankstown-Lidcombe Hospital , Sydney, New South Wales ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Matthews","sequence":"additional","affiliation":[{"name":"St Vincent's Hospital Sydney , Sydney, New South Wales ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z","family":"Valaydon","sequence":"additional","affiliation":[{"name":"Western Health , Melbourne, Victoria ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1490-0547","authenticated-orcid":false,"given":"D","family":"Wong","sequence":"additional","affiliation":[{"name":"Austin Health , Melbourne, Victoria ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8206-2664","authenticated-orcid":false,"given":"M","family":"Littlejohn","sequence":"additional","affiliation":[{"name":"Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity , Melbourne, Victoria ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J A","family":"Holmes","sequence":"additional","affiliation":[{"name":"St Vincent's Hospital , Melbourne, Victoria ,","place":["Australia"]},{"name":"Department of Medicine, The University of Melbourne , Victoria ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P A","family":"Revill","sequence":"additional","affiliation":[{"name":"Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity , Melbourne, Victoria ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A J","family":"Thompson","sequence":"additional","affiliation":[{"name":"St Vincent's Hospital , Melbourne, Victoria ,","place":["Australia"]},{"name":"Department of Medicine, The University of Melbourne , Victoria ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4252-086X","authenticated-orcid":false,"given":"N","family":"Warner","sequence":"additional","affiliation":[{"name":"Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity , Melbourne, Victoria ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"2026031710041788700_jiaf569-B1","volume-title":"Global hepatitis report 2024: action for access in low- and middle-income countries","author":"World Health Organization","year":"2024"},{"key":"2026031710041788700_jiaf569-B2","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1053\/j.gastro.2021.11.002","article-title":"Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: an international, multicenter, multiethnic cohort (RETRACT-B study)","volume":"162","author":"Hirode","year":"2022","journal-title":"Gastroenterology"},{"key":"2026031710041788700_jiaf569-B3","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.jhep.2022.01.007","article-title":"Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels","volume":"76","author":"Sonneveld","year":"2022","journal-title":"J Hepatol"},{"key":"2026031710041788700_jiaf569-B4","doi-asserted-by":"crossref","first-page":"934","DOI":"10.3390\/v12090934","article-title":"The yin and the yang of treatment for chronic hepatitis B\u2014when to start, when to stop nucleos(t)ide analogue therapy","volume":"12","author":"Hall","year":"2020","journal-title":"Viruses"},{"key":"2026031710041788700_jiaf569-B5","first-page":"1629","article-title":"Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis","volume":"71","author":"Hall","year":"2022","journal-title":"Gut"},{"key":"2026031710041788700_jiaf569-B6","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/apt.16968","article-title":"Stopping nucleot(s)ide analogues in non-cirrhotic HBeAg-negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with low baseline HBsAg levels","volume":"56","author":"Hall","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"2026031710041788700_jiaf569-B7","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.cmi.2017.12.013","article-title":"Long-term incidence and predictors of hepatitis B surface antigen loss after discontinuing nucleoside analogues in noncirrhotic chronic hepatitis B patients","volume":"24","author":"Chen","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2026031710041788700_jiaf569-B8","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jhep.2016.08.009","article-title":"The role of quantitative hepatitis B surface antigen revisited","volume":"66","author":"Cornberg","year":"2017","journal-title":"J Hepatol"},{"key":"2026031710041788700_jiaf569-B9","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/jvh.13211","article-title":"Predictors of hepatitis B surface antigen loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in noncirrhotic HBeAg-negative chronic hepatitis B","volume":"27","author":"Papatheodoridi","year":"2020","journal-title":"J Viral Hepatitis"},{"key":"2026031710041788700_jiaf569-B10","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1111\/liv.16029","article-title":"High end-of-treatment hepatitis B core-related antigen levels predict hepatitis flare after stopping nucleot(s)ide analogue therapy","volume":"44","author":"Hume","year":"2024","journal-title":"Liver Int"},{"key":"2026031710041788700_jiaf569-B11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jmii.2022.06.002","article-title":"End-of-treatment HBsAg, HBcrAg and HBV RNA predict the risk of off-treatment ALT flares in chronic hepatitis B patients","volume":"56","author":"Brakenhoff","year":"2023","journal-title":"J Microbiol Immunol Infect"},{"key":"2026031710041788700_jiaf569-B12","first-page":"29","article-title":"New biomarkers of hepatitis B virus infection: HBV RNA and HBcrAg, new kids on the block?","volume":"29","author":"Lim","year":"2022","journal-title":"Clin Mol Hepatol"},{"key":"2026031710041788700_jiaf569-B13","doi-asserted-by":"crossref","first-page":"e0188","DOI":"10.1097\/HC9.0000000000000188","article-title":"Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participants","volume":"7","author":"Thompson","year":"2023","journal-title":"Hepatol Commun"},{"key":"2026031710041788700_jiaf569-B14","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1111\/liv.13716","article-title":"ALT flares during nucleotide analogue therapy are associated with HBsAg loss in genotype A HBeAg-positive chronic hepatitis B","volume":"38","author":"Wong","year":"2018","journal-title":"Liver Int"},{"key":"2026031710041788700_jiaf569-B15","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.3390\/ijms23031552","article-title":"Hepatitis B flare in hepatitis B e antigen-negative patients: a complicated cascade of innate and adaptive immune responses","volume":"23","author":"Chang","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026031710041788700_jiaf569-B16","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jac\/dkab360","article-title":"Highly significant differences in HBsAg kinetics among patients with two types of hepatitis B flare, with and without retreatment","volume":"77","author":"Jeng","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2026031710041788700_jiaf569-B17","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/hep.31525","article-title":"Hepatitis B flare after cessation of nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B: to retreat or not to retreat","volume":"73","author":"Liaw","year":"2021","journal-title":"Hepatology"},{"key":"2026031710041788700_jiaf569-B18","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/sj.icb.7100009","article-title":"Immunopathogenesis of hepatitis B virus infection","volume":"85","author":"Chang","year":"2007","journal-title":"Immunol Cell Biol"},{"key":"2026031710041788700_jiaf569-B19","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1473-3099(01)00172-4","article-title":"Immunology of hepatitis B infection","volume":"2","author":"Jung","year":"2002","journal-title":"Lancet Infect Dis"},{"issue":"S5","key":"2026031710041788700_jiaf569-B20","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.1002\/hep.22945","article-title":"Reactivation of hepatitis B","volume":"49","author":"Hoofnagle","year":"2009","journal-title":"Hepatology"},{"key":"2026031710041788700_jiaf569-B21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m2200","article-title":"Hepatitis B virus persistence and reactivation","volume":"370","author":"Shi","year":"2020","journal-title":"BMJ"},{"key":"2026031710041788700_jiaf569-B22","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/MCG.0000000000001520","article-title":"Hepatitis B reactivation: a review of clinical guidelines","volume":"55","author":"Wang","year":"2021","journal-title":"J Clin Gastroenterol"},{"key":"2026031710041788700_jiaf569-B23","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev.iy.13.040195.000333","article-title":"Hepatitis B virus immunopathogenesis","volume":"13","author":"Chisari","year":"1995","journal-title":"Ann Rev Immunol"},{"key":"2026031710041788700_jiaf569-B24","first-page":"493","article-title":"Analysis of viral proteins in circulating immune complexes from chronic carriers of hepatitis B virus","volume":"84","author":"Madalinski","year":"1991","journal-title":"Clin Exp Immunol"},{"key":"2026031710041788700_jiaf569-B25","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0022-1759(80)90257-4","article-title":"Detection and quantitation of hepatitis B surface antigen immune complexes (HBsAg-ICs) by an antigen-specific method. II. Circulating immune complexes (CICs) in patients with hepatitis B and asymptomatic HBsAg carriers","volume":"35","author":"Anh-Tuan","year":"1980","journal-title":"J Immunol Methods"},{"key":"2026031710041788700_jiaf569-B26","doi-asserted-by":"crossref","first-page":"582292","DOI":"10.3389\/fimmu.2020.582292","article-title":"The multiple functions of B cells in chronic HBV infection","volume":"11","author":"Cai","year":"2020","journal-title":"Front Immunol"},{"key":"2026031710041788700_jiaf569-B27","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jhep.2021.07.031","article-title":"Role of anti-HBs in functional cure of HBeAg + chronic hepatitis B patients infected with HBV genotype A","volume":"76","author":"Xu","year":"2022","journal-title":"J Hepatol"},{"key":"2026031710041788700_jiaf569-B28","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/jmv.24732","article-title":"Genotypic profiles of hepatitis B in African immigrants and their clinical relevance","volume":"89","author":"Thurnheer","year":"2017","journal-title":"J Med Virol"},{"key":"2026031710041788700_jiaf569-B29","doi-asserted-by":"crossref","first-page":"e784-e793","DOI":"10.1016\/j.cgh.2020.12.005","article-title":"Prediction of sustained response after nucleo(s)tide analogue cessation using HBsAg and HBcrAg levels: a multicenter study (CREATE)","volume":"20","author":"Sonneveld","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026031710041788700_jiaf569-B30","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.14309\/ajg.0000000000002203","article-title":"Incidence of hepatic decompensation after nucleos(t)ide analog withdrawal: results from a large, international, multiethnic cohort of patients with chronic hepatitis B (RETRACT-B study)","volume":"118","author":"Hirode","year":"2023","journal-title":"Off J Am College Gastroenterol"},{"key":"2026031710041788700_jiaf569-B31","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1093\/jac\/dkac409","article-title":"Combined baseline HBcrAg and end-of-treatment HBsAg predict HBV relapse after entecavir or tenofovir cessation","volume":"78","author":"Tseng","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2026031710041788700_jiaf569-B32","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.jhep.2014.08.033","article-title":"Hepatitis B flares in chronic hepatitis B: pathogenesis, natural course, and management","volume":"61","author":"Chang","year":"2014","journal-title":"J Hepatol"},{"key":"2026031710041788700_jiaf569-B33","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1093\/infdis\/jix690","article-title":"Distinct relapse rates and risk predictors after discontinuing tenofovir and entecavir therapy","volume":"217","author":"Su","year":"2018","journal-title":"J Infect Dis"},{"key":"2026031710041788700_jiaf569-B34","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1093\/infdis\/jiy350","article-title":"Contrasting timing of virological relapse after discontinuation of tenofovir or entecavir in hepatitis B e antigen\u2013negative patients","volume":"218","author":"H\u00f6ner zu Siederdissen","year":"2018","journal-title":"J Infect Dis"},{"key":"2026031710041788700_jiaf569-B35","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1136\/gutjnl-2016-312653","article-title":"Induction of IFN-\u03bb3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection","volume":"67","author":"Murata","year":"2018","journal-title":"Gut"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaf569\/65293201\/jiaf569.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/233\/3\/e621\/65293201\/jiaf569.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/233\/3\/e621\/65293201\/jiaf569.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T14:04:26Z","timestamp":1773756266000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/233\/3\/e621\/8323611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,11,14]]},"published-print":{"date-parts":[[2026,3,17]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaf569","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3,15]]},"published":{"date-parts":[[2025,11,14]]}}}